Verrica Pharmaceuticals

VRCA · NASDAQ

$3.47+$0.03 (+0.87%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.44

VRCA analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $14.11 (+306.6% upside)

Low: $9.09
Now: $3.47
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

VRCA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	May 26, 2026	Initiates	Buy	$12.00	43%
Brookline Capital	Dec 18, 2025	Upgrade	Hold → Buy	$17.00	31%

The case for and against

Updated Jun 12, 2025

Bull case

Verrica Pharmaceuticals Inc. has demonstrated significant growth in the volume of dispensed applicator units, with a notable 29% increase in Q3 2024 compared to Q2 2024, and a sustained 12% growth in Q4 2024, reaching 8,654 units which translated to approximately $5.9 million in sales. The company's efforts to normalize inventory levels are expected to enhance the alignment between product availability and consumer demand, potentially boosting future sales performance. Additionally, despite recent cost restructuring and a downsized sales force, the upward trend in dispensed units suggests a resilient market demand that could benefit the company in the upcoming quarters.

Bear case

Verrica Pharmaceuticals faces significant challenges due to competition from cheaper treatment options available in the market, which could hinder product pricing and payor coverage for its treatments. The company reported a substantial loss of $16.2 million in the fourth quarter of 2024, raising concerns about its financial viability and the need for additional funding for operations and debt repayment. Furthermore, uncertainties surrounding the clinical trials of its product candidate, Ycanth, coupled with potential supply chain disruptions, add to the risks affecting its growth prospects and overall business stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.